Erlotinib and gefitinib are first generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI). Afatinib is a second generation pan-Her EGFR TKI. All three TKIs have demonstrated superiority to… Click to show full abstract
Erlotinib and gefitinib are first generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI). Afatinib is a second generation pan-Her EGFR TKI. All three TKIs have demonstrated superiority to chemotherapy in the first line setting in patients harboring an EGFR mutation in the EURTAC [1], IPASS [2], LUX-LUNG 3 [3] and LUX-LUNG 6 [4] trials. This article describes the case of a patient treated at a Cancer Centre in Taiwan and at the British Columbia Cancer Agency in Canada. This patient experienced a remarkable response to a number of different systemic treatments. Despite not having a detectable EGFR mutation, he had a positive and prolonged response to all three EGFR TKIs. This case challenges current treatment paradigms for the treatment of a NSCLC patient whose tumour does not have an activating EGFR mutation.
               
Click one of the above tabs to view related content.